 | • レポートコード：MRC2-11QY01434 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はヒト呼吸器合胞体ウイルス薬のグローバル市場について調査・分析したレポートです。種類別（承認薬、適応外薬）市場規模、用途別（臨床診断、検査室内科医院、検査室病院）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ヒト呼吸器合胞体ウイルス薬の競争状況、市場シェア ・世界のヒト呼吸器合胞体ウイルス薬市場：種類別市場規模 2015年-2020年（承認薬、適応外薬） ・世界のヒト呼吸器合胞体ウイルス薬市場：種類別市場規模予測 2021年-2026年（承認薬、適応外薬） ・世界のヒト呼吸器合胞体ウイルス薬市場：用途別市場規模 2015年-2020年（臨床診断、検査室内科医院、検査室病院） ・世界のヒト呼吸器合胞体ウイルス薬市場：用途別市場規模予測 2021年-2026年（臨床診断、検査室内科医院、検査室病院） ・北米のヒト呼吸器合胞体ウイルス薬市場分析：米国、カナダ ・ヨーロッパのヒト呼吸器合胞体ウイルス薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのヒト呼吸器合胞体ウイルス薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のヒト呼吸器合胞体ウイルス薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのヒト呼吸器合胞体ウイルス薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、AbbVie、GSK、Teva Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway. Treatment is limited to supportive care, including oxygen therapy and more advanced breathing support with CPAP or nasal high flow oxygen.
One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period.
Market Analysis and Insights: Global Human Respiratory Syncytial Virus Drugs Market
The global Human Respiratory Syncytial Virus Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Human Respiratory Syncytial Virus Drugs Scope and Market Size
Human Respiratory Syncytial Virus Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Human Respiratory Syncytial Virus Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Human Respiratory Syncytial Virus Drugs market is segmented into
Approved Drugs
Off-Label Drugs
Segment by Application, the Human Respiratory Syncytial Virus Drugs market is segmented into
Clinical Diagnostic
Laboratories Physicians’ Office
Laboratories Hospitals
Regional and Country-level Analysis
The Human Respiratory Syncytial Virus Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Human Respiratory Syncytial Virus Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Human Respiratory Syncytial Virus Drugs Market Share Analysis
Human Respiratory Syncytial Virus Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Human Respiratory Syncytial Virus Drugs business, the date to enter into the Human Respiratory Syncytial Virus Drugs market, Human Respiratory Syncytial Virus Drugs product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca
AbbVie
GSK
Teva Pharmaceutical
…
1 Study Coverage
1.1 Human Respiratory Syncytial Virus Drugs Product Introduction
1.2 Market Segments
1.3 Key Human Respiratory Syncytial Virus Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Human Respiratory Syncytial Virus Drugs Market Size Growth Rate by Type
1.4.2 Approved Drugs
1.4.3 Off-Label Drugs
1.5 Market by Application
1.5.1 Global Human Respiratory Syncytial Virus Drugs Market Size Growth Rate by Application
1.5.2 Clinical Diagnostic
1.5.3 Laboratories Physicians’ Office
1.5.4 Laboratories Hospitals
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Human Respiratory Syncytial Virus Drugs Market Size, Estimates and Forecasts
2.1.1 Global Human Respiratory Syncytial Virus Drugs Revenue 2015-2026
2.1.2 Global Human Respiratory Syncytial Virus Drugs Sales 2015-2026
2.2 Global Human Respiratory Syncytial Virus Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Human Respiratory Syncytial Virus Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Human Respiratory Syncytial Virus Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Human Respiratory Syncytial Virus Drugs Competitor Landscape by Players
3.1 Human Respiratory Syncytial Virus Drugs Sales by Manufacturers
3.1.1 Human Respiratory Syncytial Virus Drugs Sales by Manufacturers (2015-2020)
3.1.2 Human Respiratory Syncytial Virus Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Human Respiratory Syncytial Virus Drugs Revenue by Manufacturers
3.2.1 Human Respiratory Syncytial Virus Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Human Respiratory Syncytial Virus Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Human Respiratory Syncytial Virus Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Human Respiratory Syncytial Virus Drugs Revenue in 2019
3.2.5 Global Human Respiratory Syncytial Virus Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Human Respiratory Syncytial Virus Drugs Price by Manufacturers
3.4 Human Respiratory Syncytial Virus Drugs Manufacturing Base Distribution, Product Types
3.4.1 Human Respiratory Syncytial Virus Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Human Respiratory Syncytial Virus Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Human Respiratory Syncytial Virus Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Human Respiratory Syncytial Virus Drugs Market Size by Type (2015-2020)
4.1.1 Global Human Respiratory Syncytial Virus Drugs Sales by Type (2015-2020)
4.1.2 Global Human Respiratory Syncytial Virus Drugs Revenue by Type (2015-2020)
4.1.3 Human Respiratory Syncytial Virus Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Human Respiratory Syncytial Virus Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Human Respiratory Syncytial Virus Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Human Respiratory Syncytial Virus Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Human Respiratory Syncytial Virus Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Human Respiratory Syncytial Virus Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Human Respiratory Syncytial Virus Drugs Market Size by Application (2015-2020)
5.1.1 Global Human Respiratory Syncytial Virus Drugs Sales by Application (2015-2020)
5.1.2 Global Human Respiratory Syncytial Virus Drugs Revenue by Application (2015-2020)
5.1.3 Human Respiratory Syncytial Virus Drugs Price by Application (2015-2020)
5.2 Human Respiratory Syncytial Virus Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Human Respiratory Syncytial Virus Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Human Respiratory Syncytial Virus Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Human Respiratory Syncytial Virus Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Human Respiratory Syncytial Virus Drugs by Country
6.1.1 North America Human Respiratory Syncytial Virus Drugs Sales by Country
6.1.2 North America Human Respiratory Syncytial Virus Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Type
6.3 North America Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Human Respiratory Syncytial Virus Drugs by Country
7.1.1 Europe Human Respiratory Syncytial Virus Drugs Sales by Country
7.1.2 Europe Human Respiratory Syncytial Virus Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Type
7.3 Europe Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Human Respiratory Syncytial Virus Drugs by Region
8.1.1 Asia Pacific Human Respiratory Syncytial Virus Drugs Sales by Region
8.1.2 Asia Pacific Human Respiratory Syncytial Virus Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Type
8.3 Asia Pacific Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Human Respiratory Syncytial Virus Drugs by Country
9.1.1 Latin America Human Respiratory Syncytial Virus Drugs Sales by Country
9.1.2 Latin America Human Respiratory Syncytial Virus Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Type
9.3 Central & South America Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Human Respiratory Syncytial Virus Drugs by Country
10.1.1 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales by Country
10.1.2 Middle East and Africa Human Respiratory Syncytial Virus Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Human Respiratory Syncytial Virus Drugs Products Offered
11.1.5 AstraZeneca Related Developments
11.2 AbbVie
11.2.1 AbbVie Corporation Information
11.2.2 AbbVie Description and Business Overview
11.2.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AbbVie Human Respiratory Syncytial Virus Drugs Products Offered
11.2.5 AbbVie Related Developments
11.3 GSK
11.3.1 GSK Corporation Information
11.3.2 GSK Description and Business Overview
11.3.3 GSK Sales, Revenue and Gross Margin (2015-2020)
11.3.4 GSK Human Respiratory Syncytial Virus Drugs Products Offered
11.3.5 GSK Related Developments
11.4 Teva Pharmaceutical
11.4.1 Teva Pharmaceutical Corporation Information
11.4.2 Teva Pharmaceutical Description and Business Overview
11.4.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Teva Pharmaceutical Human Respiratory Syncytial Virus Drugs Products Offered
11.4.5 Teva Pharmaceutical Related Developments
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Human Respiratory Syncytial Virus Drugs Products Offered
11.1.5 AstraZeneca Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Human Respiratory Syncytial Virus Drugs Market Estimates and Projections by Region
12.1.1 Global Human Respiratory Syncytial Virus Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Human Respiratory Syncytial Virus Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Human Respiratory Syncytial Virus Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Human Respiratory Syncytial Virus Drugs Sales Forecast (2021-2026)
12.2.2 North America: Human Respiratory Syncytial Virus Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Human Respiratory Syncytial Virus Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Human Respiratory Syncytial Virus Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Human Respiratory Syncytial Virus Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Human Respiratory Syncytial Virus Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Human Respiratory Syncytial Virus Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Human Respiratory Syncytial Virus Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Human Respiratory Syncytial Virus Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Human Respiratory Syncytial Virus Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Human Respiratory Syncytial Virus Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Human Respiratory Syncytial Virus Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Human Respiratory Syncytial Virus Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Human Respiratory Syncytial Virus Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Human Respiratory Syncytial Virus Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Human Respiratory Syncytial Virus Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Human Respiratory Syncytial Virus Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Human Respiratory Syncytial Virus Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Human Respiratory Syncytial Virus Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Human Respiratory Syncytial Virus Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Human Respiratory Syncytial Virus Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Human Respiratory Syncytial Virus Drugs Market Segments
Table 2. Ranking of Global Top Human Respiratory Syncytial Virus Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Human Respiratory Syncytial Virus Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Approved Drugs
Table 5. Major Manufacturers of Off-Label Drugs
Table 6. Global Human Respiratory Syncytial Virus Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 7. Global Human Respiratory Syncytial Virus Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 8. Global Human Respiratory Syncytial Virus Drugs Sales by Regions 2015-2020 (K MT)
Table 9. Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Regions (2015-2020)
Table 10. Global Human Respiratory Syncytial Virus Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Human Respiratory Syncytial Virus Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 12. Global Human Respiratory Syncytial Virus Drugs Sales Share by Manufacturers (2015-2020)
Table 13. Global Human Respiratory Syncytial Virus Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Human Respiratory Syncytial Virus Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Respiratory Syncytial Virus Drugs as of 2019)
Table 15. Human Respiratory Syncytial Virus Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Human Respiratory Syncytial Virus Drugs Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Human Respiratory Syncytial Virus Drugs Price (2015-2020) (USD/MT)
Table 18. Human Respiratory Syncytial Virus Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Human Respiratory Syncytial Virus Drugs Product Type
Table 20. Date of International Manufacturers Enter into Human Respiratory Syncytial Virus Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Human Respiratory Syncytial Virus Drugs Sales by Type (2015-2020) (K MT)
Table 23. Global Human Respiratory Syncytial Virus Drugs Sales Share by Type (2015-2020)
Table 24. Global Human Respiratory Syncytial Virus Drugs Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Human Respiratory Syncytial Virus Drugs Revenue Share by Type (2015-2020)
Table 26. Human Respiratory Syncytial Virus Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 27. Global Human Respiratory Syncytial Virus Drugs Sales by Application (2015-2020) (K MT)
Table 28. Global Human Respiratory Syncytial Virus Drugs Sales Share by Application (2015-2020)
Table 29. North America Human Respiratory Syncytial Virus Drugs Sales by Country (2015-2020) (K MT)
Table 30. North America Human Respiratory Syncytial Virus Drugs Sales Market Share by Country (2015-2020)
Table 31. North America Human Respiratory Syncytial Virus Drugs Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Human Respiratory Syncytial Virus Drugs Revenue Market Share by Country (2015-2020)
Table 33. North America Human Respiratory Syncytial Virus Drugs Sales by Type (2015-2020) (K MT)
Table 34. North America Human Respiratory Syncytial Virus Drugs Sales Market Share by Type (2015-2020)
Table 35. North America Human Respiratory Syncytial Virus Drugs Sales by Application (2015-2020) (K MT)
Table 36. North America Human Respiratory Syncytial Virus Drugs Sales Market Share by Application (2015-2020)
Table 37. Europe Human Respiratory Syncytial Virus Drugs Sales by Country (2015-2020) (K MT)
Table 38. Europe Human Respiratory Syncytial Virus Drugs Sales Market Share by Country (2015-2020)
Table 39. Europe Human Respiratory Syncytial Virus Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Human Respiratory Syncytial Virus Drugs Revenue Market Share by Country (2015-2020)
Table 41. Europe Human Respiratory Syncytial Virus Drugs Sales by Type (2015-2020) (K MT)
Table 42. Europe Human Respiratory Syncytial Virus Drugs Sales Market Share by Type (2015-2020)
Table 43. Europe Human Respiratory Syncytial Virus Drugs Sales by Application (2015-2020) (K MT)
Table 44. Europe Human Respiratory Syncytial Virus Drugs Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Human Respiratory Syncytial Virus Drugs Sales by Region (2015-2020) (K MT)
Table 46. Asia Pacific Human Respiratory Syncytial Virus Drugs Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Human Respiratory Syncytial Virus Drugs Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Human Respiratory Syncytial Virus Drugs Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Human Respiratory Syncytial Virus Drugs Sales by Type (2015-2020) (K MT)
Table 50. Asia Pacific Human Respiratory Syncytial Virus Drugs Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Human Respiratory Syncytial Virus Drugs Sales by Application (2015-2020) (K MT)
Table 52. Asia Pacific Human Respiratory Syncytial Virus Drugs Sales Market Share by Application (2015-2020)
Table 53. Latin America Human Respiratory Syncytial Virus Drugs Sales by Country (2015-2020) (K MT)
Table 54. Latin America Human Respiratory Syncytial Virus Drugs Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Human Respiratory Syncytial Virus Drugs Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Human Respiratory Syncytial Virus Drugs Revenue Market Share by Country (2015-2020)
Table 57. Latin America Human Respiratory Syncytial Virus Drugs Sales by Type (2015-2020) (K MT)
Table 58. Latin America Human Respiratory Syncytial Virus Drugs Sales Market Share by Type (2015-2020)
Table 59. Latin America Human Respiratory Syncytial Virus Drugs Sales by Application (2015-2020) (K MT)
Table 60. Latin America Human Respiratory Syncytial Virus Drugs Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales by Country (2015-2020) (K MT)
Table 62. Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Human Respiratory Syncytial Virus Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Human Respiratory Syncytial Virus Drugs Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales by Type (2015-2020) (K MT)
Table 66. Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales by Application (2015-2020) (K MT)
Table 68. Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales Market Share by Application (2015-2020)
Table 69. AstraZeneca Corporation Information
Table 70. AstraZeneca Description and Major Businesses
Table 71. AstraZeneca Human Respiratory Syncytial Virus Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 72. AstraZeneca Product
Table 73. AstraZeneca Recent Development
Table 74. AbbVie Corporation Information
Table 75. AbbVie Description and Major Businesses
Table 76. AbbVie Human Respiratory Syncytial Virus Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. AbbVie Product
Table 78. AbbVie Recent Development
Table 79. GSK Corporation Information
Table 80. GSK Description and Major Businesses
Table 81. GSK Human Respiratory Syncytial Virus Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. GSK Product
Table 83. GSK Recent Development
Table 84. Teva Pharmaceutical Corporation Information
Table 85. Teva Pharmaceutical Description and Major Businesses
Table 86. Teva Pharmaceutical Human Respiratory Syncytial Virus Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Teva Pharmaceutical Product
Table 88. Teva Pharmaceutical Recent Development
Table 89. Global Human Respiratory Syncytial Virus Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 90. Global Human Respiratory Syncytial Virus Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 91. Global Human Respiratory Syncytial Virus Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 92. Global Human Respiratory Syncytial Virus Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 93. North America: Human Respiratory Syncytial Virus Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 94. North America: Human Respiratory Syncytial Virus Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 95. Europe: Human Respiratory Syncytial Virus Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 96. Europe: Human Respiratory Syncytial Virus Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 97. Asia Pacific: Human Respiratory Syncytial Virus Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 98. Asia Pacific: Human Respiratory Syncytial Virus Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 99. Latin America: Human Respiratory Syncytial Virus Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 100. Latin America: Human Respiratory Syncytial Virus Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 101. Middle East and Africa: Human Respiratory Syncytial Virus Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 102. Middle East and Africa: Human Respiratory Syncytial Virus Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 104. Key Challenges
Table 105. Market Risks
Table 106. Main Points Interviewed from Key Human Respiratory Syncytial Virus Drugs Players
Table 107. Human Respiratory Syncytial Virus Drugs Customers List
Table 108. Human Respiratory Syncytial Virus Drugs Distributors List
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Respiratory Syncytial Virus Drugs Product Picture
Figure 2. Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Approved Drugs Product Picture
Figure 4. Off-Label Drugs Product Picture
Figure 5. Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Application in 2020 & 2026
Figure 6. Clinical Diagnostic
Figure 7. Laboratories Physicians' Office
Figure 8. Laboratories Hospitals
Figure 9. Human Respiratory Syncytial Virus Drugs Report Years Considered
Figure 10. Global Human Respiratory Syncytial Virus Drugs Market Size 2015-2026 (US$ Million)
Figure 11. Global Human Respiratory Syncytial Virus Drugs Sales 2015-2026 (K MT)
Figure 12. Global Human Respiratory Syncytial Virus Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Region (2015-2020)
Figure 14. Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Region in 2019
Figure 15. Global Human Respiratory Syncytial Virus Drugs Revenue Market Share by Region (2015-2020)
Figure 16. Global Human Respiratory Syncytial Virus Drugs Revenue Market Share by Region in 2019
Figure 17. Global Human Respiratory Syncytial Virus Drugs Sales Share by Manufacturer in 2019
Figure 18. The Top 10 and 5 Players Market Share by Human Respiratory Syncytial Virus Drugs Revenue in 2019
Figure 19. Human Respiratory Syncytial Virus Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Type (2015-2020)
Figure 21. Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Type in 2019
Figure 22. Global Human Respiratory Syncytial Virus Drugs Revenue Market Share by Type (2015-2020)
Figure 23. Global Human Respiratory Syncytial Virus Drugs Revenue Market Share by Type in 2019
Figure 24. Global Human Respiratory Syncytial Virus Drugs Market Share by Price Range (2015-2020)
Figure 25. Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Application (2015-2020)
Figure 26. Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Application in 2019
Figure 27. Global Human Respiratory Syncytial Virus Drugs Revenue Market Share by Application (2015-2020)
Figure 28. Global Human Respiratory Syncytial Virus Drugs Revenue Market Share by Application in 2019
Figure 29. North America Human Respiratory Syncytial Virus Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 30. North America Human Respiratory Syncytial Virus Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 31. North America Human Respiratory Syncytial Virus Drugs Sales Market Share by Country in 2019
Figure 32. North America Human Respiratory Syncytial Virus Drugs Revenue Market Share by Country in 2019
Figure 33. U.S. Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 34. U.S. Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. Canada Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 36. Canada Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. North America Human Respiratory Syncytial Virus Drugs Market Share by Type in 2019
Figure 38. North America Human Respiratory Syncytial Virus Drugs Market Share by Application in 2019
Figure 39. Europe Human Respiratory Syncytial Virus Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 40. Europe Human Respiratory Syncytial Virus Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 41. Europe Human Respiratory Syncytial Virus Drugs Sales Market Share by Country in 2019
Figure 42. Europe Human Respiratory Syncytial Virus Drugs Revenue Market Share by Country in 2019
Figure 43. Germany Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 44. Germany Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. France Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 46. France Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. U.K. Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 48. U.K. Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Italy Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 50. Italy Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Russia Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 52. Russia Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Europe Human Respiratory Syncytial Virus Drugs Market Share by Type in 2019
Figure 54. Europe Human Respiratory Syncytial Virus Drugs Market Share by Application in 2019
Figure 55. Asia Pacific Human Respiratory Syncytial Virus Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 56. Asia Pacific Human Respiratory Syncytial Virus Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 57. Asia Pacific Human Respiratory Syncytial Virus Drugs Sales Market Share by Region in 2019
Figure 58. Asia Pacific Human Respiratory Syncytial Virus Drugs Revenue Market Share by Region in 2019
Figure 59. China Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 60. China Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Japan Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 62. Japan Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. South Korea Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 64. South Korea Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. India Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 66. India Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Australia Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 68. Australia Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Taiwan Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 70. Taiwan Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Indonesia Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 72. Indonesia Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Thailand Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 74. Thailand Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Malaysia Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 76. Malaysia Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Philippines Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 78. Philippines Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Vietnam Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 80. Vietnam Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Asia Pacific Human Respiratory Syncytial Virus Drugs Market Share by Type in 2019
Figure 82. Asia Pacific Human Respiratory Syncytial Virus Drugs Market Share by Application in 2019
Figure 83. Latin America Human Respiratory Syncytial Virus Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 84. Latin America Human Respiratory Syncytial Virus Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 85. Latin America Human Respiratory Syncytial Virus Drugs Sales Market Share by Country in 2019
Figure 86. Latin America Human Respiratory Syncytial Virus Drugs Revenue Market Share by Country in 2019
Figure 87. Mexico Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 88. Mexico Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Brazil Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 90. Brazil Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Argentina Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 92. Argentina Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Latin America Human Respiratory Syncytial Virus Drugs Market Share by Type in 2019
Figure 94. Latin America Human Respiratory Syncytial Virus Drugs Market Share by Application in 2019
Figure 95. Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 96. Middle East and Africa Human Respiratory Syncytial Virus Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 97. Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales Market Share by Country in 2019
Figure 98. Middle East and Africa Human Respiratory Syncytial Virus Drugs Revenue Market Share by Country in 2019
Figure 99. Turkey Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 100. Turkey Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Saudi Arabia Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 102. Saudi Arabia Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. U.A.E Human Respiratory Syncytial Virus Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 104. U.A.E Human Respiratory Syncytial Virus Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Middle East and Africa Human Respiratory Syncytial Virus Drugs Market Share by Type in 2019
Figure 106. Middle East and Africa Human Respiratory Syncytial Virus Drugs Market Share by Application in 2019
Figure 107. North America Human Respiratory Syncytial Virus Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 108. North America Human Respiratory Syncytial Virus Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 109. Europe Human Respiratory Syncytial Virus Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 110. Europe Human Respiratory Syncytial Virus Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Asia Pacific Human Respiratory Syncytial Virus Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 112. Asia Pacific Human Respiratory Syncytial Virus Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Latin America Human Respiratory Syncytial Virus Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 114. Latin America Human Respiratory Syncytial Virus Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 116. Middle East and Africa Human Respiratory Syncytial Virus Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Porter's Five Forces Analysis
Figure 118. Channels of Distribution
Figure 119. Distributors Profiles
Figure 120. Bottom-up and Top-down Approaches for This Report
Figure 121. Data Triangulation
Figure 122. Key Executives Interviewed
呼吸器合胞体ウイルス診断の世界市場（～2026年） Products of the respiratory syncytial virus diagnostics market includes direct fluorescent antibody (DFA) method, rapid antigen diagnostic test (RADTs), molecular diagnostics, chromatographic immunoassay, diagnostic imaging, gel microdroplets, flow cytometry, and others. North America dominates the …- 呼吸器合胞体ウイルス付着糖タンパク質の世界市場（～2026年） Market Analysis and Insights: Global Respiratory Syncytial Virus Attachment Glycoprotein Market The global Respiratory Syncytial Virus Attachment Glycoprotein market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Respiratory…
- 呼吸器合胞体ウイルス（RSV）治療薬の世界市場（～2026年） Market Analysis and Insights: Global Respiratory Syncytial Virus (RSV) Therapeutics Market The global Respiratory Syncytial Virus (RSV) Therapeutics market size is projected to reach US$ 599.6 million by 2026, from US$ 564.7 million in 2020, at a CAGR of 5.7%% during 2021-2026. Global Respiratory Sy…
- ヒト免疫不全ウイルス（HIV）の世界市場（～2026年） HIV (Human immunodeficiency virus) is a retrovirus which causes HIV infection and attacks the CD-4 cells (T-cells) in the immune system of human body. HIV reduces the number of T-cells in the body and makes the immune system vulnerable to life-threatening infections and cancers. An infected person c…
- ヒト免疫不全ウイルス（HIV）-1治療薬の世界市場（～2026年） The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and can…